Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Stomach Neoplasms 24 Colorectal Neoplasms 12 Colonic Neoplasms 9 Rectal Neoplasms 6 Carcinoma, Hepatocellular 6 Pancreatic Neoplasms 5 Esophageal Squamous Cell Carcinoma 4 Carcinoma, Non-Small-Cell Lung 4 Breast Neoplasms 4 Biliary Tract Neoplasms 4 Unspecified Adult Solid Tumor, Protocol Specific 3 Squamous Cell Carcinoma of Head and Neck 3 Head and Neck Neoplasms 3 Gallbladder Neoplasms 3 Esophageal Neoplasms 3 HER2-positive Gastric Cancer 2 Cholangiocarcinoma 2 Uterine Cervical Neoplasms 1 Stage IA Pancreatic Adenocarcinoma 1 Solid Tumor 1 Recurrence 1 Nasopharyngeal Carcinoma 1 Mouth Neoplasms 1 Malignant Neoplasms of Digestive Organs 1 Lung Neoplasms 1 Klatskin Tumor 1 Immunotherapy 1 Gastric Adenocarcinoma 1 Fruquintinib 1 For Patients With Colorectal Cancer Liver Metastases Who Were Not Able to Curative Surgical Resection.Focused on the Treatment Effect With the Quintuple Method 1

Interventions

raltitrexed 1 potassium oxonate 1 gimeracil 1 Tegafur 1 S 1 (combination) 1 Irinotecan 1 HMPL-013 1 Capecitabine 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Fruquintinib × Tegafur × Clear all

NCT06427005 2025-01-22

Fruquintinib Plus S-1 and Raltitrexed (RSF) for MCRC

West China Hospital

Phase 2 Unknown

Fruquintinib

Data powered by HemOnc (CC BY 4.0) Colophon ⚡